Clinical trials: Resistant Arterial Hypertension
Uncontrolled or Resistant Hypertension
A Trial of HRS-1780 in Participants With Uncontrolled Hypertension or Resistant Hypertension.
The study is being conducted to evaluate the efficacy and safety of HRS-1780 in participants with uncontrolled hypertension or resistant hypertension.
- Trial name
- NCT07708441
- Testing
- HRS-1780 tablet
- Where
- 2 sites in China
- Volunteers
- 914 people
- Sponsor
- Shandong Suncadia Medicine Co., Ltd.
Hypertension, Vascular Diseases
The RADIANCE II Pivotal Study: A Study of the ReCor Medical Paradise System in Stage II Hypertension
The objective of the RADIANCE II Pivotal study is to demonstrate the effectiveness and safety of the Paradise System in subjects with Stage 2 hypertension on 0-2 medications at the time of consent.
- Conditions
- Hypertension, Vascular Diseases, Cardiovascular Diseases
- Trial name
- RADIANCE-II (NCT03614260)
- Testing
- Paradise Renal Denervation System, Renal Angiogram
- Where
- 47 sites in United States, Belgium and 6 more
- Volunteers
- 224 people
- Sponsor
- ReCor Medical, Inc.
Inflammation, Hypertension
Efficacy Study of Pioglitazone and Ramipril Combination Therapy in Treating Non-diabetic Hypertensive Patients.
The purpose of this study is to determine the effects of pioglitazone, once daily (QD), on low grade inflammation and vascular function in hypertensive patients.
- Trial name
- NCT00770497
- Testing
- Pioglitazone, Pioglitazone and ramipril, Ramipril
- Where
- 13 sites in Germany
- Volunteers
- 172 people
- Sponsor
- Takeda
Resistant Hypertension
Symplicity China Study
The Symplicity China study will evaluate the real-world long-term safety, efficacy, and durability of the Symplicity Spyral system in a population of approximately 500 renal denervation treated subjects with up to 36 months of…
- Trial name
- NCT07081243
- Testing
- Symplicity Spyral Renal Denervation System
- Where
- China
- Volunteers
- 500 people
- Sponsor
- Medtronic Vascular
Uncontrolled Hypertension, Resistant Hypertension
A Study to Investigate the Efficacy and Safety of Baxdrostat in Participants With Uncontrolled Hypertension on Two or More Medications Including Participants With Resistant Hypertension
This is a Phase III, multicentre, randomised, double-blinded, placebo-controlled, parallel group study to evaluate the safety, tolerability and effect of 1 or 2 mg baxdrostat versus placebo, administered once daily (QD) orally…
- Trial name
- BaxHTN (NCT06034743)
- Testing
- Baxdrostat
- Where
- 263 sites in United States, Argentina and 27 more
- Volunteers
- 796 people
- Sponsor
- AstraZeneca
Hypertension, Renal Denervation
International First-in-Human Study of the EnligHTN Generation 2 System in Patients With Drug-resistant Uncontrolled Hypertension
The purpose of this First-in-Human Clinical investigation is to evaluate the safety and performance of the St. Jude Medical EnligHTN™ Generation 2 Renal Denervation System for the treatment of patients with drug-resistant…
- Trial name
- EnligHTN III (NCT01836146)
- Testing
- EnligHTN™ Renal Artery Ablation Catheter
- Where
- 6 sites in Australia, New Zealand
- Volunteers
- 39 people
- Sponsor
- Abbott Medical Devices
Difficult to Control Hypertension
To Evaluate the Safety and Efficacy of MANP in Subjects With Difficult to Control/ Resistant Hypertension
This is a Phase 2 dose-titration study designed to evaluate the safety and efficacy of MANP subcutaneous injection compared to placebo in reducing baseline daytime systolic blood pressure (SBP), derived from 24-hour ambulatory…
- Trial name
- BOLD-HTN (NCT06343298)
- Testing
- MANP
- Where
- 23 sites in United States
- Volunteers
- 120 people
- Sponsor
- E-Star BioTech, LLC
Hypertension
EnligHTN IV Trial - Multicenter Sham-controlled RCT of Renal Denervation for Hypertension
The purpose of the EnligHTN IV clinical investigation is to demonstrate the safety and effectiveness of the EnligHTN™ Renal Denervation System in the treatment of subjects with drug-resistant uncontrolled hypertension.
- Trial name
- EnligHTN-IV (NCT01903187)
- Testing
- EnligHTN Renal Denervation
- Where
- 3 sites in United States
- Volunteers
- 4 people
- Sponsor
- Abbott Medical Devices
High Blood Pressure
Verification of the Efficacy and Safety of the BAROSTIM NEO System in the Treatment of Drug Resistant Hypertension
To assess the long-term safety and efficacy of the BAROSTIM NEO System in trial (NCT01471834) participants.
- Trial name
- NCT01471834
- Testing
- BAROSTIM NEO System, Medical Management
- Where
- 9 sites in Canada, Germany and 1 more
- Volunteers
- 40 people
- Sponsor
- CVRx, Inc.
Patients, Resistant Hypertension
Safety and Efficacy Study of LHW090 in Resistant Hypertension Patients
The purpose of the present study was to determine whether LHW090 displays the clinical safety and efficacy profile to support further development in patients with resistant hypertension.
- Trial name
- NCT02515331
- Testing
- LHW090
- Where
- 16 sites in United States, Denmark and 4 more
- Volunteers
- 64 people
- Sponsor
- Novartis Pharmaceuticals
Pulmonary Hypertension
Evaluate Effect of Optison on Pulmonary Artery Systolic Pressure (PASP) and Pulmonary Vascular Resistance (PVR).
The design of this study is to conduct a comprehensive safety evaluation of the pulmonary hemodynamic effects of Optison. The study is being conducted in subjects referred for cardiac catheterization for clinical reasons.
- Trial name
- NCT00878878
- Testing
- Optison (Perflutren Protein-Type A Microspheres Injectable Suspension), Dextrose
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- GE Healthcare
Hypertension
Observational Study to Investigate Resistant Hypertension Prevalence in Korean General Hospitals
Study Objectives The study is to identify prevalence, demography and clinical characteristics of patients with resistant hypertension among hypertensive patients who have been treated in general hospitals in Korea from Jan 2012…
- Trial name
- Teveten_RH (NCT01753206)
- Where
- South Korea
- Volunteers
- 1,579 people
- Sponsor
- Handok Inc.
Metabolic Syndrome
Metabolic Syndrome Observation on a Regional Basis
The aim of the study is to assess the prevalence of Metabolic Syndrome in Italy on a regional basis, defined according to NCEP/ATPIII Guidelines criteria.
- Trial name
- ORSA Umbria (NCT00933010)
- Where
- 3 sites in Italy
- Volunteers
- 1,600 people
- Sponsor
- AstraZeneca
Hypertension
DORADO - Fixed Doses of Darusentan as Compared to Placebo in Resistant Hypertension
This is a research study of a new experimental drug called darusentan. Darusentan is not currently approved by the U.S. Food and Drug Administration (FDA) for use in the United States, which means that a doctor cannot prescribe…
- Trial name
- NCT00330369
- Testing
- Darusentan
- Where
- 115 sites in United States, Argentina and 9 more
- Volunteers
- 352 people
- Sponsor
- Gilead Sciences
Hypertension, Resistant to Conventional Therapy
Safety and Efficacy Study of Extracorporeal Shockwave Therapy in the Treatment of Patients With Resistant Hypertension
Low intensity shockwaves have been proven in animal and human studies to increase tissue perfusion, promote angiogenesis and tissue regeneration and improve neural function.
- Trial name
- RHT (NCT02042066)
- Testing
- Omnispec model Vascuspec
- Where
- Israel
- Volunteers
- 10 people
- Sponsor
- Medispec
Hypertension Resistant to Conventional Therapy, Bradycardia
Moderato System: A Double-Blind Randomized Trial Ver 1.1
The purpose of this double blind randomized study is the evaluation of the safety and efficacy of the Moderato System. The Moderato implantable pulse generator is indicated for patients who have hypertension and also require a…
- Conditions
- Hypertension Resistant to Conventional Therapy, Bradycardia, Atrioventricular Block
- Trial name
- NCT02837445
- Testing
- PHC ON, PHC OFF
- Where
- 12 sites in Austria, Belgium and 5 more
- Volunteers
- 70 people
- Sponsor
- BackBeat Medical Inc
PAH
CXA-10 Study in Subjects With Pulmonary Arterial Hypertension
This is a Phase 2, multicenter, open-label extension (OLE) of study CXA-10-301, to evaluate the long term safety and efficacy of daily dosing of CXA-10.
- Trial name
- NCT04053543
- Testing
- CXA-10
- Where
- 37 sites in United States, United Kingdom
- Volunteers
- 33 people
- Sponsor
- Complexa, Inc.
Hypertension
Aliskiren Plus HCTZ Compared to Aliskiren in Metabolic Syndrome Patients With Stage 2 Systolic Hypertension
The purpose of the study is to evaluate the blood pressure lowering effect and safety of aliskiren in combination with Hydrochlorothiazide (HCTZ) compared to aliskiren monotherapy when given to metabolic syndrome patients with…
- Trial name
- AIMS (NCT00797316)
- Testing
- Aliskiren, Hydrochlorothiazide
- Where
- United States
- Volunteers
- 532 people
- Sponsor
- Novartis
Hypertension, Pulmonary, Lung Diseases, Interstitial
Study of TX000045 in Participants With Pulmonary Hypertension Due to Interstitial Lung Disease
The primary purpose of this study is to assess the effect of TX000045 on pulmonary vascular resistance (PVR) in participants with pulmonary hypertension secondary to interstitial lung disease (PH-ILD) and to assess the safety and…
- Trial name
- NCT07473700
- Testing
- TX000045
- Where
- 16 sites in United States, Poland and 4 more
- Volunteers
- 25 people
- Sponsor
- Tectonic Operating Company, Inc.
Hypertension
Randomized Controlled Trial of Renal Denervation for Resistant Hypertension
Hypertension represents a significant global public health problem, contributing to vascular and renal morbidity, cardiovascular mortality, and economic burden.
- Trial name
- NCT02900729
- Testing
- Radiofrequency ablation catheter, Amlodipine, losartan potassium and hydrochlorothiazide
- Where
- 13 sites in China
- Volunteers
- 254 people
- Sponsor
- Shanghai WiseGain Medical Devices Co., Ltd.